Min Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Min Yang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Tao Liu
Department of Traditional Chinese Medicine, Rheumatology Center of Integrated Medicine, The General Hospital of Western Theater Command, PLA, Chengdu, China
3 shared publicationsYong Luo
Department of Traditional Chinese Medicine, Rheumatology Center of Integrated Medicine, The General Hospital of Western Theater Command, PLA, Chengdu, China
3 shared publicationsJiao Yan
The General Hospital of Western Theater Command, PLA
2 shared publicationsJie Tao
The General Hospital of Western Theater Command, PLA
2 shared publicationsMingyang Guo
Department of Traditional Chinese Medicine, Rheumatology Center of Integrated Medicine, Chengdu Military General Hospital, Chengdu, China
2 shared publicationsXing-Biao Yang
Department of Traditional Chinese Medicine, Rheumatology Center of Integrated Medicine, The General Hospital of Western Theater Command, PLA, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 23 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
FAT1 inhibits the proliferation of DLBCL cells via increasing the m6A modification of YAP1 mRNA
Emerging evidence shows that FAT atypical cadherin 1 (FAT1) mutations occur in lymphoma and are associated with poorer overall survival. Considering that diffuse large B cell lymphoma (DLBCL) is the category of lymphoma with the highest incidence rate, this study aims to explore the role of FAT1 in DLBCL. The findings demonstrate that FAT1 inhibits the proliferation of DLBCL cell lines by downregulating the expression of YAP1 rather than by altering its cellular localization. Mechanistic analysis via meRIP-qPCR/luciferase reporter assays showed that FAT1 increases the m6A modification of YAP1 mRNA 3′UTR and the subsequent binding of heterogeneous nuclear ribonucleoprotein D (HNRNPD) to the m6A modified YAP1 mRNA, thus decreasing the stability of YAP1 mRNA. Furthermore, FAT1 increases YAP1 mRNA 3′UTR m6A modification by decreasing the activity of the TGFβ-Smad2/3 pathway and the subsequent expression of ALKBH5, which is regulated at the transcriptional level by Smad2/3. Collectively, these results reveal that FAT1 inhibits the proliferation of DLBCL cells by increasing the m6A modification of the YAP1 mRNA 3’UTR via the TGFβ-Smad2/3-ALKBH5 pathway. The findings of this study therefore indicate that FAT1 exerts anti-tumor effects in DLBCL and may represent a novel target in the treatment of this form of lymphoma.
- 23 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessFAT1 inhibits the proliferation of DLBCL cells via increasing the m6A modification of YAP1 mRNA
Emerging evidence shows that FAT atypical cadherin 1 (FAT1) mutations occur in lymphoma and are associated with poorer overall survival. Considering that diffuse large B cell lymphoma (DLBCL) is the category of lymphoma with the highest incidence rate, this study aims to explore the role of FAT1 in DLBCL. The findings demonstrate that FAT1 inhibits the proliferation of DLBCL cell lines by downregulating the expression of YAP1 rather than by altering its cellular localization. Mechanistic analysis via meRIP-qPCR/luciferase reporter assays showed that FAT1 increases the m6A modification of YAP1 mRNA 3′UTR and the subsequent binding of heterogeneous nuclear ribonucleoprotein D (HNRNPD) to the m6A modified YAP1 mRNA, thus decreasing the stability of YAP1 mRNA. Furthermore, FAT1 increases YAP1 mRNA 3′UTR m6A modification by decreasing the activity of the TGFβ-Smad2/3 pathway and the subsequent expression of ALKBH5, which is regulated at the transcriptional level by Smad2/3. Collectively, these results reveal that FAT1 inhibits the proliferation of DLBCL cells by increasing the m6A modification of the YAP1 mRNA 3’UTR via the TGFβ-Smad2/3-ALKBH5 pathway. The findings of this study therefore indicate that FAT1 exerts anti-tumor effects in DLBCL and may represent a novel target in the treatment of this form of lymphoma.
- Open Access
- 21 March 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-15
Establishing a prediction model of severe acute mountain sickness using machine learning of support vector machine recursive feature elimination
Severe acute mountain sickness (sAMS) can be life-threatening, but little is known about its genetic basis. The study was aimed to explore the genetic susceptibility of sAMS for the purpose of prediction, using microarray data from 112 peripheral blood mononuclear cell (PBMC) samples of 21 subjects, who were exposed to very high altitude (5260 m), low barometric pressure (406 mmHg), and hypobaric hypoxia (VLH) at various timepoints. We found that exposure to VLH activated gene expression in leukocytes, resulting in an inverted CD4/CD8 ratio that interacted with other phenotypic risk factors at the genetic level. A total of 2286 underlying risk genes were input into the support vector machine recursive feature elimination (SVM-RFE) system for machine learning, and a model with satisfactory predictive accuracy and clinical applicability was established for sAMS screening using ten featured genes with significant predictive power. Five featured genes (EPHB3, DIP2B, RHEBL1, GALNT13, and SLC8A2) were identified upstream of hypoxia- and/or inflammation-related pathways mediated by microRNAs as potential biomarkers for sAMS. The established prediction model of sAMS holds promise for clinical application as a genetic screening tool for sAMS.
- 21 March 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-15
Open AccessEstablishing a prediction model of severe acute mountain sickness using machine learning of support vector machine recursive feature elimination
Severe acute mountain sickness (sAMS) can be life-threatening, but little is known about its genetic basis. The study was aimed to explore the genetic susceptibility of sAMS for the purpose of prediction, using microarray data from 112 peripheral blood mononuclear cell (PBMC) samples of 21 subjects, who were exposed to very high altitude (5260 m), low barometric pressure (406 mmHg), and hypobaric hypoxia (VLH) at various timepoints. We found that exposure to VLH activated gene expression in leukocytes, resulting in an inverted CD4/CD8 ratio that interacted with other phenotypic risk factors at the genetic level. A total of 2286 underlying risk genes were input into the support vector machine recursive feature elimination (SVM-RFE) system for machine learning, and a model with satisfactory predictive accuracy and clinical applicability was established for sAMS screening using ten featured genes with significant predictive power. Five featured genes (EPHB3, DIP2B, RHEBL1, GALNT13, and SLC8A2) were identified upstream of hypoxia- and/or inflammation-related pathways mediated by microRNAs as potential biomarkers for sAMS. The established prediction model of sAMS holds promise for clinical application as a genetic screening tool for sAMS.
- Open Access
- 9 January 2023
- Published by Springer Nature in Research Square
Establishing a prediction model of severe acute mountain sickness using deep learning of support vector machine recursive feature elimination
Background Severe acute mountain sickness (sAMS) can be life-threatening, but little is known about its genetic basis. Using microarray genotype data and phenotype data for deep learning, we aimed to explore the genetic susceptibility of sAMS for the purpose of prediction. Methods The study was based on microarray data from 112 peripheral blood mononuclear cell (PBMC) samples of 21 subjects, who were exposed to very high altitude (5260 m), low barometric pressure (406 mmHg), and hypobaric hypoxia (VLH) at various timepoints. Subjects were investigated for the interplay effects between multiple phenotypic risk factors, and the underlying risk genes were identified to establish the prediction model of sAMS using the support vector machine recursive feature elimination (SVM-RFE) method. Results Exposure to VLH activated the gene expression in leukocytes, resulting in inverted CD4/CD8 ratio which interplayed with other phenotypic risk factors at the genetic level (P < 0.001). 2291 underlying risk genes were input to SVM-RFE system for deep learning, and a prediction model was established with satisfactory predictive accuracy (C-index = 1), and clinical applicability for sAMS using ten featured genes with significant predictive power (P < 0.05). Five featured genes (EPHB3,DIP2B,RHEBL1,GALNT13, andSLC8A2) were identified as the upstream of hypoxia and/ or inflammation-related pathways mediated by micorRNAs as potential biomarkers for sAMS. Conclusions The established prediction model of sAMS holds promise to be clinically applied as a genetic screening tool for sAMS. More studies are needed to establish the role of the featured genes as biomarker for sAMS.
- 9 January 2023
- Published by Springer Nature in Research Square
Open AccessEstablishing a prediction model of severe acute mountain sickness using deep learning of support vector machine recursive feature elimination
Background Severe acute mountain sickness (sAMS) can be life-threatening, but little is known about its genetic basis. Using microarray genotype data and phenotype data for deep learning, we aimed to explore the genetic susceptibility of sAMS for the purpose of prediction. Methods The study was based on microarray data from 112 peripheral blood mononuclear cell (PBMC) samples of 21 subjects, who were exposed to very high altitude (5260 m), low barometric pressure (406 mmHg), and hypobaric hypoxia (VLH) at various timepoints. Subjects were investigated for the interplay effects between multiple phenotypic risk factors, and the underlying risk genes were identified to establish the prediction model of sAMS using the support vector machine recursive feature elimination (SVM-RFE) method. Results Exposure to VLH activated the gene expression in leukocytes, resulting in inverted CD4/CD8 ratio which interplayed with other phenotypic risk factors at the genetic level (P < 0.001). 2291 underlying risk genes were input to SVM-RFE system for deep learning, and a prediction model was established with satisfactory predictive accuracy (C-index = 1), and clinical applicability for sAMS using ten featured genes with significant predictive power (P < 0.05). Five featured genes (EPHB3,DIP2B,RHEBL1,GALNT13, andSLC8A2) were identified as the upstream of hypoxia and/ or inflammation-related pathways mediated by micorRNAs as potential biomarkers for sAMS. Conclusions The established prediction model of sAMS holds promise to be clinically applied as a genetic screening tool for sAMS. More studies are needed to establish the role of the featured genes as biomarker for sAMS.
- 1 October 2018
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (10) , 1752-1764.e1
The Effect of Puerarin on Carotid Intima-media Thickness in Patients With Active Rheumatoid Arthritis: A Randomized Controlled Trial
- 1 October 2018
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (10) , 1752-1764.e1
The Effect of Puerarin on Carotid Intima-media Thickness in Patients With Active Rheumatoid Arthritis: A Randomized Controlled Trial
- 1 November 2013
- Published by Elsevier in Medical Hypotheses
- Vol. 81 (5) , 948-953
Scube regulates synovial angiogenesis-related signaling
- 1 November 2013
- Published by Elsevier in Medical Hypotheses
- Vol. 81 (5) , 948-953
Scube regulates synovial angiogenesis-related signaling